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Background.– Botulinum toxin type A (BoNT-A) injections are a key treatment
in the interdisciplinary management of patients with spasticity. Here, we present
interim analyses of characteristics of physicians participating in the SPACE
study.
Methods.– SPACE, an international, observational study of the safety and effec-
tiveness of several BoNT-As, followed previously BoNT-naïve patients with
spasticity for up to 2 years. Data regarding physicians’ speciality, medical expe-
rience, BoNT-A dosing preferences and treatment approaches were collected.
Results.– These interim analyses included 230 physicians* from Europe (66.1%),
Canada (6.1%), Mexico (4.8%) and Russia (5.7%). Most physicians were neu-
rologists (50.9%) or physiatrists (36.5%). Treating physicians had a median
15 years’ experience in medical practice (range 1–36 years; experience with
BoNT-A, 0–25 years [median 8.5 years]). Most physicians (60.9%) would inject
higher BoNT-A doses if permitted by product labelling. For 48.9% of patients
(317/648)*, the BoNT-A treatment decision was agreed by a multidisciplinary
team.
*Interim analyses – data were not yet available for all physicians/patients.
Conclusions.– Data from the SPACE study will further improve our understan-
ding of physician practice with BoNT-A for treating patients with spasticity
in a routine setting, identify challenges in managing these patients and aid
optimisation of treatment approaches.
http://dx.doi.org/10.1016/j.rehab.2014.03.167
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Background.– Botulinum toxin A (BoNT-A) injections are a key treatment for
patients with spasticity. Here, we present interim analyses of patient baseline
characteristics in SPACE, an international, non-interventional study of the safety
and effectiveness of BoNT-A formulations.
Methods.– SPACE followed BoNT treatment-naïve patients with spasticity (any
aetiology) for up to 2 years. Data collected included baseline disease characte-
ristics and key treatment goals, as agreed by each patient and physician.
Results.– These interim analyses include 648 patients* (61.9% male, mean
[standard deviation (SD)] age 54.8 [15.6] years). Causes of spasticity inclu-
ded stroke (66.4%), multiple sclerosis (9.7%) and brain injury (6.5%). Most
patients (79.3%) were hemiplegic (diplegic, 11.7%; quadriplegic, 7.9%). Median
time since the spasticity-causing event was 2.0 years (range 0–63 years). Many
patients (57.4%) reported spasticity-related pain (mild, 20.1%; moderate, 28.1%;
severe, 9.3%). The most common key treatment goals were “improvement in
mobility” (20.5%), “improvement in dexterity and reaching” (15.7%) and “pain
relief” (11.9%).
*Interim analyses – data were not yet available for all patients.
Conclusions.– Data from SPACE will help to further define the role of BoNT-
A as part of a multimodal management approach for focal spasticity and aid
patients in this diverse population achieve individual treatment goals.
http://dx.doi.org/10.1016/j.rehab.2014.03.168
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Background.– In adult, stroke patients maximal recommended dose of onabo-
tulinumtoxinA is 600 UI, with reported generalised side-effects at 800 UI [1].
Doses up to 840 UI of IncobotulinumtoxinA have been reported in a case without
side effects, but more precise data are lacking [2]. We report the use of high doses
of incobotulinumtoxinA in a group of patients.
Methods.– Clinical records of 46 stroke survivors (19 females) with spastic
hemiplegia treated with IncobotulinumtoxinA (100 UI:2 mL of 0.9% NaCl), with
doses ≥ 500 UI (maximal dose < 14 UI/Kg) were reviewed. Muscles, dose for
each muscle, Ashworth grade before and 1 month after treatment and side effects
were recorded.
Results.– Mean incobotulinumtoxinA dose was 638.3 ± 106.9 UI. Mean Ash-
worth score at injected muscle was 3.39 ± 0.94 (median 3, IQR 3–5) before
treatment and 1.22 ± 1.04 (median 1, IQR 0–5) after treatment. Twenty-three
patients had ≥ 700 UI. Each patient had a mean of 9.65 muscles treated. No
adverse events were noted in this group.
Conclusions.– In our retrospective analysis, incobotulinumtoxinA at high doses
in multifocal treatment for spasticity showed to be effective and safe.
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Background.– In rodents, botulinum toxin type A (BoNT-A) is retrogradely
transported to second-order neurons in the central nervous system (CNS). At
present, time data in humans are missing.
